GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (FRA:CUL) » Definitions » Debt-to-EBITDA

Aspira Womens Health (FRA:CUL) Debt-to-EBITDA : -0.17 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Aspira Womens Health Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Aspira Womens Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.91 Mil. Aspira Womens Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €1.70 Mil. Aspira Womens Health's annualized EBITDA for the quarter that ended in Dec. 2023 was €-15.03 Mil. Aspira Womens Health's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.17.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Aspira Womens Health's Debt-to-EBITDA or its related term are showing as below:

FRA:CUL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.29   Med: -0.13   Max: -0.06
Current: -0.16

During the past 13 years, the highest Debt-to-EBITDA Ratio of Aspira Womens Health was -0.06. The lowest was -0.29. And the median was -0.13.

FRA:CUL's Debt-to-EBITDA is ranked worse than
100% of 105 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.96 vs FRA:CUL: -0.16

Aspira Womens Health Debt-to-EBITDA Historical Data

The historical data trend for Aspira Womens Health's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aspira Womens Health Debt-to-EBITDA Chart

Aspira Womens Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.11 -0.29 -0.13 -0.12 -0.15

Aspira Womens Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.17 -0.15 -0.14 -0.14 -0.17

Competitive Comparison of Aspira Womens Health's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Aspira Womens Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aspira Womens Health's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's Debt-to-EBITDA falls into.



Aspira Womens Health Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Aspira Womens Health's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.912 + 1.703) / -17.105
=-0.15

Aspira Womens Health's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.912 + 1.703) / -15.032
=-0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Aspira Womens Health  (FRA:CUL) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Aspira Womens Health Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Aspira Womens Health (FRA:CUL) Business Description

Traded in Other Exchanges
Address
12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.

Aspira Womens Health (FRA:CUL) Headlines

No Headlines